ClinicalTrials.gg

Program

BHV-1300

A development code.

Its studies are mostly in Graves Disease, led by Biohaven Therapeutics.

Furthest: phase 3, since Jun 16, 20263 company-led studies, 3 open or runningNext primary completion: Sep 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Biohaven Therapeutics33 open or runningphase 3since Jun 16, 2026May 12, 2025Sep 2027phase 1 · NCT06980649

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 12, 2025First study: phase 1 study in Graves DiseaseFirst studyNCT06980649 · 15 planned · United States, Australia
  2. Jun 16, 2026Phase 3 study in Graves DiseasePhase 3 reachedNCT07661056 · 300 planned · United States, Canada, Puerto Rico
  3. Oct 22, 2026Phase 3 study in Graves DiseaseNCT07901244 · 356 planned

Ahead

  1. Sep 2027Primary completion: phase 1 study in Graves DiseaseNCT06980649
  2. Jan 2028Primary completion: phase 3 study in Graves DiseaseNCT07661056
  3. Dec 2028Primary completion: phase 3 study in Graves DiseaseNCT07901244

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07901244Graves Disease3Not yet recruitingDec 2028356
NCT07661056Graves Disease · United States, Canada, Puerto Rico3RecruitingJan 2028300
NCT06980649Graves Disease · United States, Australia1RecruitingSep 202715

How it is read

Names in the registry

  • “BHV-1300”, 3 entries

Codes read as this program: BHV1300.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.